Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
Executive Summary
FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition
You may also be interested in...
FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
ViroPharma has fired another shot across FDA's bow in the continuing battle over approval standards for generic oral vancomycin, charging in a petition supplement that the Office of Generic Drugs' decision to change bioequivalence methods for this antibiotic "was fraught with irregularities.
FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
ViroPharma has fired another shot across FDA's bow in the continuing battle over approval standards for generic oral vancomycin, charging in a petition supplement that the Office of Generic Drugs' decision to change bioequivalence methods for this antibiotic "was fraught with irregularities.
Generic Vancocin Gets Cmte. Endorsement, But So Do New Brand Products
When the Pharmaceutical Science and Clinical Pharmacology Advisory Committee endorsed dissolution data for establishing bioequivalence of generic versions of Vancocin, it not only paved the way for generic applicants, but it also highlighted the need for additional, more accommodating forms of the drug